SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-18-031972
Filing Date
2018-05-10
Accepted
2018-05-10 08:19:46
Documents
59
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q a18-8673_110q.htm 10-Q 863013
2 EX-31.1 a18-8673_1ex31d1.htm EX-31.1 12084
3 EX-31.2 a18-8673_1ex31d2.htm EX-31.2 12106
4 EX-32.1 a18-8673_1ex32d1.htm EX-32.1 7887
  Complete submission text file 0001104659-18-031972.txt   4181550

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cldx-20180331.xml EX-101.INS 873687
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cldx-20180331.xsd EX-101.SCH 32627
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cldx-20180331_cal.xml EX-101.CAL 48555
8 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT cldx-20180331_lab.xml EX-101.LAB 342369
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cldx-20180331_pre.xml EX-101.PRE 251414
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cldx-20180331_def.xml EX-101.DEF 136210
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 18820620
SIC: 2835 In Vitro & In Vivo Diagnostic Substances